SingHealth

Belkins
The SingHealth Duke-NUS Academic Medical Centre draws on the collective strengths of SingHealth and Duke-NUS Medical School to drive the transformation of healthcare and provide affordable, accessible, quality healthcare. With over 40 clinical specialties, a network of acute hospitals, national specialty centres, polyclinics and community hospitals, it delivers comprehensive, multi-disciplinary and integrated care. To enhance community care, the new Outram Community Hospital on SGH Campus will be completed in 2020.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AVENUEB CREATES A PATH TO SUCCESS FOR BIOLOGY STUDENTS

UC Davis | April 14, 2020

news image

The Genentech Foundation has donated $2.5 million to the University of California, Davis, College of Biological Sciences — the college’s largest single gift ever — to fund a program that will help biology students transferring from community college. Called AvenueB, the program will provide financial support and preparatory programs for students going to four-year university. According to the Campaign for College Opportunity, students transferring from community colleges to a U...

Read More

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

news image

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More

LILLY AND SITRYX SIGN $880 MILLION+ 5-YEAR DEVELOPMENT DEAL

BioSpace | March 31, 2020

news image

Eli Lilly and Oxford, England-based Sitryx entered an exclusive global licensing and research collaboration. The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases. Under the terms of the deal, Lilly is paying Sitryx $50 million up front. Lilly will also make a $10 million equity investment in the company. Sitryx will be eligible for development milestones up to $820 million, in addition to commercialization milestones and royalty pay...

Read More

CELL AND GENE THERAPY

XYLYX BIO PARTNERS WITH INVENTIA LIFE SCIENCE TO DEVELOP TISSUE-SPECIFIC, DIGITALLY-PRINTED BIOINKS FOR DRUG DISCOVERY

Xylyx Bio, Inc. | September 02, 2021

news image

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting provides promising tools to quickly and more precisely culture cells to develop...

Read More
news image

AVENUEB CREATES A PATH TO SUCCESS FOR BIOLOGY STUDENTS

UC Davis | April 14, 2020

The Genentech Foundation has donated $2.5 million to the University of California, Davis, College of Biological Sciences — the college’s largest single gift ever — to fund a program that will help biology students transferring from community college. Called AvenueB, the program will provide financial support and preparatory programs for students going to four-year university. According to the Campaign for College Opportunity, students transferring from community colleges to a U...

Read More
news image

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More
news image

LILLY AND SITRYX SIGN $880 MILLION+ 5-YEAR DEVELOPMENT DEAL

BioSpace | March 31, 2020

Eli Lilly and Oxford, England-based Sitryx entered an exclusive global licensing and research collaboration. The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases. Under the terms of the deal, Lilly is paying Sitryx $50 million up front. Lilly will also make a $10 million equity investment in the company. Sitryx will be eligible for development milestones up to $820 million, in addition to commercialization milestones and royalty pay...

Read More
news image

CELL AND GENE THERAPY

XYLYX BIO PARTNERS WITH INVENTIA LIFE SCIENCE TO DEVELOP TISSUE-SPECIFIC, DIGITALLY-PRINTED BIOINKS FOR DRUG DISCOVERY

Xylyx Bio, Inc. | September 02, 2021

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting provides promising tools to quickly and more precisely culture cells to develop...

Read More